Teva Pharma has advised that Androderm® will be removed from the Pharmaceutical Benefits Scheme (PBS) from 1 April 2023, as follows:

Androderm® Transdermal Patch
Testosterone 5mg/24 hours
ARTG 82398

Androderm® will remain available to patients as a private product.

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Teva Pharma on 1800 288 382 or your pharmacist at HPS Pharmacies.

Download PDF

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates